Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Nieuwe door OMF gefinancierde wetenschappelijke publicatie: Een nano-elektronische op bloed gebaseerde diagnostische test voor ME/CVS

Dr. Ron Davis, directeur van de Wetenschappelijke Adviesraad van OMF, licht de publicatie in PNAS over de nanonaald toe (29 april 2019)

Lees dit artikel op Facebook

Lees dit artikel op de website van OMF

Lees alle vertalingen van dit en andere artikelen op de website van OMF

Een studie die de nanonaald beschrijft, is gepubliceerd in de Proceedings of the National Academy of Sciences. Ronald W. Davis, PhD, is er de senior auteur van. Rahim Esfandyarpour, PhD, is de hoofdauteur. De nanonaald is een test die wijzigingen meet in immuuncellen met hun bloedplasma ten gevolge van stress, opgewekt  door zout. Binnenin de nanonaald interfereren de immuuncellen met een kleine elektrische stroom. De verandering in de elektrische activiteit heeft een rechtstreekse correlatie met de gezondheidstoestand van het afgenomen monster. De test, die zich nog in een testfase bevindt, is gebaseerd op de manier waarop de immuuncellen van iemand reageren op stress. Met bloedstalen van 40 personen — 20 met ME/CVS en 20 zonder — levert de test nauwkeurige resultaten op, waarbij alle patiënten gemarkeerd werden en geen enkele van de gezonde individuen.

 

Klik hier op de video te bekijken.

Klik hier om de samenvatting en de volledige tekst te lezen op PNAS.

Klik hier om de aankondiging van Stanford te lezen.

 

 

OMF dankt Team Dutch US voor deze vertaling.

Stay Informed

Be the first to hear our research news.

Subscribe Now.

No thanks

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

 

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of five prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo